AIRS · AirSculpt Technologies, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on AIRS. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About AIRS · AirSculpt Technologies, Inc.
AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States and Canada. The company offers AirSculpt, a body contouring treatment that removes fat and tightens skin while sculpting targeted areas of the body in a minimally invasive procedure. It also provides AirSculpt+, a procedure that permanently removes fat and tightens the skin with unparalleled precision and finesse; and AirSculpt Smooth, an advanced cellulite removal tool. In addition, it provides fat removal procedures across treatment areas, such as the stomach, back, and buttocks; and fat transfer procedures that transfers the patient's own fat cells to enhance the buttocks, breasts, hips, aging hands, or other areas. Further, the company's body contouring procedures include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. Additionally, it operates various centers. The company was founded in 2012 and is headquartered in Miami Beach, Florida.
Live Quote
HOLD (score -1) · 12-1 mom 2.3% · RSI 45.4 · above_both · -60.5% from high
Targets blend Wall Street consensus (1 analysts: low $4.50 / mean $4.50 / high $4.50) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Score is 1, far below the 60 threshold for asymmetric small-caps. The dossier flags material accounting irregularities (annual report delay and EBITDA correction) and dilution, which trigger hard anti-signal gates. Additionally, weak fundamentals (13.5x net debt/EBITDA, negative earnings), an overbought technical setup (RSI 76.6), and an insider who hedges with collars rather than showing unhedged conviction eliminate any viable trade shape.
Score is 1, far below the 60 threshold for asymmetric small-caps. The dossier flags material accounting irregularities (annual report delay and EBITDA correction) and dilution, which trigger hard anti-signal gates. Additionally, weak fundamentals (13.5x net debt/EBITDA, negative earnings), an overbought technical setup (RSI 76.6), and an insider who hedges with collars rather than showing unhedged conviction eliminate any viable trade shape.
Jorey Chernett (10% owner + Director) made three open-market purchases totaling ~$300K between March-April 2026 at $2.54-$2.91/share while simultaneously selling covered calls — a collar rather than unhedged conviction. The Q1 2026 report showed the first positive same-store sales in 2+ years, framed as a 'key turning point.' However, the stock has already tripled from its January 52-week low of $1.58 to $4.66 at time of investigation; Chernett's purchases are deeply in-the-money and he is now selling calls against his position rather than adding further. Fundamentals remain challenged: negative EPS, high leverage (D/E 70%), declining revenue, and an annual report delay due to accounting adjustments. The stock's sharp recovery limits the asymmetric upside case.